Updates are available Correction dated 2022-03-24
Click to view Correction: https://doi.org/10.1038/s41586-022-04652-x
-
Authors
Seung, Edward
Xing, Zhen
Wu, Lan
Rao, Ercole
Cortez-Retamozo, Virna
Ospina, Beatriz
Chen, Liqing
Beil, Christian
Song, Zhili
Zhang, Bailin
Levit, Mikhail
Deng, Gejing
Hebert, Andrew
Kirby, Patrick
Li, Aiqun
Poulton, Emma-Jane
Vicente, Rita
Garrigou, Audrey
Piepenhagen, Peter
Ulinski, Greg
Sanicola-Nadel, Michele
Bangari, Dinesh S. http://orcid.org/0000-0002-9909-1146
Qiu, Huawei
Pao, Lily http://orcid.org/0000-0002-7626-2782
Wiederschain, Dmitri
Wei, Ronnie
Yang, Zhi-yong http://orcid.org/0000-0002-9938-5929
Nabel, Gary J. http://orcid.org/0000-0003-0619-4419
- License Information
-
More Information
Article History
Received: 30 March 2021
Accepted: 18 January 2022
First Online: 23 February 2022
Change Date: 24 March 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41586-022-04652-x
Competing interests
: All authors are or were employees of Sanofi while engaged in this research project and may hold shares and/or stock options in the company. ModeX employees performed additional informatic evaluation of data, graphic illustration and writing at ModeX. Sanofi develops and manufactures cancer treatment medicines. ModeX is a private biotechnology company that develops multispecific antibodies for the treatment of cancers and viral diseases. G.J.N. formerly served as chief scientific officer of Sanofi. G.J.N., Z.-y.Y., E.R., R.W., E.S., L.W., Z.X., C.B. and H.Q. are listed on intellectual properties developed and owned by Sanofi related to development of novel cancer treatments.
